$CAMP News

Last published 2d ago

2d agoCAMPCAMP4 THERAPEUTICS CORPORATION (CAMP) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CAMP4 THERAPEUTICS CORPEarnings Call TranscriptsInnovation Conference here in Boston. I'm Delma Cagliatti and I'm a research analyst here at Guggenheim. And it's my pleasure to welcome Josh Mandel-Brem, the Chief Executive Officer from Camp 4 Therapeutics. It's a plea
2d agoCAMPCAMP4 THERAPEUTICS CORPORATION (CAMP) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CAMP4 THERAPEUTICS CORPEarnings Call TranscriptsInnovation Conference here in Boston. I'm Delma Cagliatti and I'm a research analyst here at Guggenheim. And it's my pleasure to welcome Josh Mandel-Brem, the Chief Executive Officer from Camp 4 Therapeutics. It's a plea
6d agoCAMPCAMP4 Reports Third Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireReceived authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and
2w agoCAMPCAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European UnionGlobeNewswireApproval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002 Company on track to
3w agoCAMPRNA Medicines: Transcriptome Engineering - CAMP4 THERAPEUTICS CORPEarnings Call TranscriptsOkay. Welcome to this session, RNA Medicine's New Targets. My name is Kane Akai. I'm the Director of Research and one of the Senior Biotech Analysts at Chardon. It's my pleasure to welcome our panelists for this session
3w agoCAMPRNA Medicines: Transcriptome Engineering - CAMP4 THERAPEUTICS CORPEarnings Call TranscriptsOkay. Welcome to this session, RNA Medicine's New Targets. My name is Kane Akai. I'm the Director of Research and one of the Senior Biotech Analysts at Chardon. It's my pleasure to welcome our panelists for this session
4w agoCAMPCAMP4 to Participate in Chardan’s 10th Annual Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
2mo agoCAMPCAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related DisorderGlobeNewswireAuthorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Company
2mo agoCAMPCAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026GlobeNewswireWATERTOWN, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
2mo agoCAMPCAMP4 to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of
3mo agoCAMPCAMP4 Reports Second Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireSecured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this
3mo agoCAMPCAMP4 Therapeutics Announces Second Closing of $100 Million Private PlacementGlobeNewswireCAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of
3mo agoCAMPCAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related DisorderGlobeNewswirePlanned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through second closing of
3mo agoCAMPCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of
4mo agoXFOR CAMPX4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of DirectorsGlobeNewswireBOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the
4mo agoCAMPCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of
5mo agoCAMPCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
6mo agoCAMPCAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related DisorderGlobeNewswireCMP-002 administration resulted in a statistically significant improvement in seizure phenotypes and parameters in a SYNGAP1 haploinsufficient mouse model Results build upon prior preclinical evidence of
6mo agoCAMPCAMP4 Reports First Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireSubmitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H
6mo agoCAMPCAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene UpregulationGlobeNewswireUsing epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscovered regRNAs in human
6mo agoCAMPCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
7mo agoCAMPCAMP4 Appoints Michael MacLean to its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
8mo agoCAMPLEERINK GLOBAL HEALTHCARE CONFERENCE - CAMP4 THERAPEUTICS CORPEarnings Call TranscriptsAll right. Welcome, everyone, to the Global Healthcare Conference of Learning Partners for 2026. I'm Lilina Sango, and I'm joined today by Josh Mendelbram, the CEO of Camphor. Josh, welcome. Great. Thank you for having u
8mo agoCAMPCAMP4 to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
8mo agoCAMPCAMP4 Reports Full Year 2025 Financial Results and Corporate HighlightsGlobeNewswireGLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic
8mo agoCAMPCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
9mo agoCAMPCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
10mo agoCAMPCAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common StockGlobeNewswireCAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or the "Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
10mo agoCAMPCAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic DiscoveriesGlobeNewswireCollaboration to leverage CAMP4's RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront and eligible for
11mo agoCAMPCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
12mo agoCAMPCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
1y agoCAMPCAMP4 Reports Third Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswireStrengthened balance sheet with private placement of up to $100 million to advance CMP-002, a first-in-class treatment for SYNGAP1-related disorders Initiated Good Laboratory Practice (GLP) toxicology studies for
1y agoCAMPCAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01GlobeNewswireCAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting
1y agoCAMPCAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related DisordersGlobeNewswireOversubscribed Financing led by Coastlands Capital with participation from new and existing investors Financing to provide $50 million in upfront proceeds with the potential for up to an additional $50 million of
1y agoCAMPCAMP4 Reports Second Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswirePresented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28th American Society of Gene and Cell
1y agoCAMPCAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual MeetingGlobeNewswireHaploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a
1y agoCAMPCAMP4 Reports First Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswirePhase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA
1y agoCAMPCAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual MeetingGlobeNewswirePreclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all
1y agoCAMPCAMP4 Reports Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswire– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in
1y agoCAMPCAMP4 Appoints Multiple Industry Veterans to its Board of DirectorsGlobeNewswireWith decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug
1y agoCAMPCalAmp Synovia to Showcase Leading Student Transportation Solutions at STN East 2025GlobeNewswireIRVINE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a global technology leader in telematics and fleet intelligence, is excited to announce its participation in the STN East Conference on March 24,
1y agoCAMPCAMP4 to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide
1y agoCAMPCAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies
1y agoCAMPCAMP4 Provides Corporate Updates and Highlights Key Upcoming MilestonesGlobeNewswireData from Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 for the treatment of urea cycle disorders (UCDs) demonstrates favorable safety resultsCompleted dosing in the first two Multiple Ascending
1y agoCAMP KRROCAMP4 Appoints John Maraganore and Rachel Meyers as Strategic AdvisorsGlobeNewswireCAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to
1y agoCAMPCAMP4 to Participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to
1y agoCAMPCAMP4 Reports Third Quarter 2024 Financial ResultsGlobeNewswire- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025- Entered
2y agoCAMPCAMP4 Announces Pricing of Initial Public OfferingGlobeNewswireCAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed
2y agoCAMPCalAmp Reaches Comprehensive Agreement to Significantly Reduce Debt, Go Private, and Strengthen Financial Flexibility to Support Innovation Through a Consensual Financial RestructuringGlobeNewswireLynrock to become the principal equity owner and take CalAmp private Continues to operate business as usual throughout this process Enhanced liquidity to invest in innovation to support customers' evolving
2y agoCAMPCalAmp Enhances School Bus Solutions Suite with Dispatch MonitorGlobeNewswireIRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with a data-driven solutions ecosystem, proudly